Home » Authors » Aaron Lorenzo

Articles by Aaron Lorenzo

Centocor's Latest Warning For Remicade Called 'Non-Event'

Aug. 27, 2004

By Aaron Lorenzo

SIGA's Biodefense Research Gets Commitments For $12M

Aug. 26, 2004

By Aaron Lorenzo

SIGA's Biodefense Research Gets Commitments For $12M

Aug. 26, 2004

By Aaron Lorenzo

More Data Analysis Helps Shape Amarin's Miraxion Phase III Plans

Aug. 25, 2004

By Aaron Lorenzo

More Data Analysis Helps Shape Amarin's Miraxion Phase III Plans

Aug. 25, 2004

By Aaron Lorenzo

More Data Analysis Helps Shape Amarin's Miraxion Phase III Plans

Aug. 25, 2004

By Aaron Lorenzo

More Data Analysis Helps Shape Amarin's Miraxion Phase III Plans

Aug. 25, 2004

By Aaron Lorenzo

ViroPharma Sheds Pleconaril; Deal Potentially Worth $75M

Aug. 24, 2004

By Aaron Lorenzo

ViroPharma Sheds Pleconaril; Deal Potentially Worth $75M

Aug. 24, 2004

By Aaron Lorenzo

Implantable Drug Firm Valera Gets $11.5M In Third Round

Aug. 23, 2004

By Aaron Lorenzo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...